Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG

References

• World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. Available at: https://covid19.who.int/. Accessed May 31, 2021.
   Google Scholar
• De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523. doi:10.1038/nrmicro.2016.81
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734. doi:10.1016/j.cmi.2020.03.026
   PubMed Web of Science ®Google Scholar
• Walsh EE, Shin JH, Falsey AR. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J Infect Dis. 2013;208(10):1634–1642. doi:10.1093/infdis/jit393
   PubMed Web of Science ®Google Scholar
• Lu R, Zhang L, Tan W, et al. Characterization of human coronavirus 229E infection among patients with respiratory symptom in Beijing, Oct-Dec, 2007. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi= Zhonghua Shiyan He Linchuang Bingduxue Zazhi= Chinese Journal of Experimental and Clinical Virology. 2009;23(5):367–370.
   PubMedGoogle Scholar
• Kaiser L, Regamey N, Roiha H, Deffernez C, Frey U. Human coronavirus NL63 associated with lower respiratory tract symptoms in early life. Pediatr Infect Dis J. 2005;24(11):1015–1017. doi:10.1097/01.inf.0000183773.80217.12
   PubMed Web of Science ®Google Scholar
• Friedman N, Alter H, Hindiyeh M, Mendelson E, Shemer Avni Y, Mandelboim M. Human coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1. Viruses. 2018;10(10):515. doi:10.3390/v10100515
   PubMed Web of Science ®Google Scholar
• Wang L, Xu X, Ruan J, Lin S, Jiang J, Ye H. Quadruple therapy for asymptomatic COVID-19 infection patients. Expert Rev Anti-Infect Ther. 2020;18:617–624.
   PubMed Web of Science ®Google Scholar
• Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200–1204.
   PubMed Web of Science ®Google Scholar
• Heidari F, Karimi E, Firouzifar M, et al. Anosmia as a prominent symptom of COVID-19 infection. Rhinology. 2020;58(3):302–303. doi:10.4193/Rhin20.140
   PubMed Web of Science ®Google Scholar
• Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603. doi:10.1001/jama.2020.12603
   PubMed Web of Science ®Google Scholar
• Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi:10.1093/cid/ciaa344
   PubMed Web of Science ®Google Scholar
• Ziegler K, Steininger P, Ziegler R, Steinmann J, Korn K, Ensser A. SARS-CoV-2 samples may escape detection because of a single point mutation in the N gene. Euro Surveill. 2020;25(39). doi:10.2807/1560-7917.ES.2020.25.39.2001650
   PubMedGoogle Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021.
   Google Scholar
• Collier DA, De Marco A, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies. MedRxiv. 2021. doi:10.1101/2021.01.19.21249840
   Google Scholar
• Nonaka CKV, Franco MM, Graf T, et al. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis. 2021;27(5):1522–1524. doi:10.3201/eid2705.210191
   PubMed Web of Science ®Google Scholar
• Jangra S, Ye C, Rathnasinghe R, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021.
   Google Scholar
• Chaturvedi R, Naidu R, Sheth S, Chakravarthy K. Efficacy of serology testing in predicting reinfection in patients with SARS-CoV-2. Disaster Med Public Health Prep. 2020;1–7. doi:10.1017/dmp.2020.216
   PubMed Web of Science ®Google Scholar
• Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. Genomics. 2020;112(5):3588–3596. doi:10.1016/j.ygeno.2020.04.016
   PubMed Web of Science ®Google Scholar
• Shahmohamadnejad S, Nabavi SF, Habtemariam S, et al. May we target double-membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection? Cell Biol Int. 2020;44(9):1770–1772. doi:10.1002/cbin.11400
   PubMed Web of Science ®Google Scholar
• Klein S, Cortese M, Winter SL, et al. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. BioRxiv. 2020.
   Google Scholar
• Viswanathan T, Arya S, Chan S-H, et al. Structural basis of RNA cap modification by SARS-CoV-2. Nat Commun. 2020;11(1):1–7. doi:10.1038/s41467-020-17496-8
   PubMedGoogle Scholar
• Rambaut A, Loman N, Pybus O et al.; on behalf of COVID-19 Genomics Consortium UK (CoG-UK). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. 2020.
   Google Scholar
• Adnan N, Khondoker MU, Rahman MS, et al. Coding-complete genome sequences and mutation profiles of nine SARS-CoV-2 strains detected from COVID-19 patients in Bangladesh. Microbiol Resour Announc. 2021;10(10):e00124–21. doi:10.1128/MRA.00124-21
   PubMed Web of Science ®Google Scholar
• Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76(24):12584–12595. doi:10.1128/JVI.76.24.12584-12595.2002
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248
   PubMed Web of Science ®Google Scholar
• Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085–1087. doi:10.1056/NEJMc2025179
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–1915. doi:10.1056/NEJMoa066092
   PubMed Web of Science ®Google Scholar
• Yang JR, Deng DT, Wu N, Yang B, Li HJ, Pan XB. Persistent viral RNA positivity during the recovery period of a patient with SARS‐CoV‐2 infection. J Med Virol. 2020;92(9):1681–1683. doi:10.1002/jmv.25940
   PubMed Web of Science ®Google Scholar
• Oishee MJ, Ali T, Jahan N, et al. COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools. Infect Drug Resist. 2021;14:1049–1082. doi:10.2147/IDR.S289629.
   Web of Science ®Google Scholar
• To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020.
   Web of Science ®Google Scholar
• Nainu F, Abidin RS, Bahar MA, et al. SARS-CoV-2 reinfection and implications for vaccine development. Hum Vaccin Immunother. 2020;16(12):3061–3073. doi:10.1080/21645515.2020.1830683
   PubMed Web of Science ®Google Scholar
• Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, et al. A case of SARS-CoV-2 reinfection in ecuador. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30910-5
   PubMed Web of Science ®Google Scholar
• Chan PKS, Lui G, Hachim A, et al. Serologic responses in healthy adult with SARS-CoV-2 reinfection, Hong Kong, August 2020. Emerg Infect Dis. 2020;26(12):3076–3078. doi:10.3201/eid2612.203833
   PubMed Web of Science ®Google Scholar
• Mulder M, van der Vegt D, Oude Munnink BB, et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1538
   Google Scholar
• Goldman JD, Wang K, Roltgen K, et al. Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report. medRxiv. 2020.
   Google Scholar
• Van Elslande J, Vermeersch P, Vandervoort K, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1330
   Web of Science ®Google Scholar
• Zucman N, Uhel F, Descamps D, Roux D, Ricard JD. Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: a case report. Clin Infect Dis. 2021. doi:10.1093/cid/ciab129
   Google Scholar
• Salzer HJF. Emerging COVID-19 reinfection four months after primary SARS-CoV-2 infection. Wien Med Wochenschr. 2021. doi:10.1007/s10354-021-00813-1
   Web of Science ®Google Scholar
• Sicsic I, Chacon AR, Zaw M, Ascher K, Abreu A, Chediak A. A case of SARS-CoV-2 reinfection in a patient with obstructive sleep apnea managed with telemedicine. BMJ Case Rep. 2021;14(2):e240496. doi:10.1136/bcr-2020-240496
   PubMedGoogle Scholar
• Novoa W, Miller H, Mattar S, Faccini-Martinez AA, Rivero R, Serrano-Coll H. A first probable case of SARS-CoV-2 reinfection in Colombia. Ann Clin Microbiol Antimicrob. 2021;20(1):7. doi:10.1186/s12941-020-00413-8
   PubMed Web of Science ®Google Scholar
• Harrington D, Kele B, Pereira S, et al. Confirmed reinfection with SARS-CoV-2 variant VOC-202012/01. Clin Infect Dis. 2021. doi:10.1093/cid/ciab014
   PubMed Web of Science ®Google Scholar
• Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52–58. doi:10.1016/S1473-3099(20)30764-7
   PubMed Web of Science ®Google Scholar
• Sil BK, Adnan N, Oishee MJ, et al. Development and evaluation of two rapid indigenous IgG-ELISA immobilized with ACE-2 binding peptides for detection neutralizing antibodies against SARS-CoV-2. medRxiv. 2020.
   Google Scholar
• Sil BK, Jahan N, Haq MA, et al. Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2. PLoS One. 2021;16(2):e0246346. doi:10.1371/journal.pone.0246346
   PubMed Web of Science ®Google Scholar
• Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292. doi:10.1016/j.cell.2020.02.058
   PubMed Web of Science ®Google Scholar
• Uddin MB, Hasan M, Harun-Al-Rashid A, Ahsan MI, Imran MAS, Ahmed SSU. Ancestral origin, antigenic resemblance and epidemiological insights of novel coronavirus (SARS-CoV-2): global burden and Bangladesh perspective. Infect Genet Evol. 2020;84:104440. doi:10.1016/j.meegid.2020.104440
   PubMed Web of Science ®Google Scholar
• Tilocca B, Soggiu A, Sanguinetti M, et al. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes Infect. 2020;22(4–5):188–194. doi:10.1016/j.micinf.2020.04.002
   PubMed Web of Science ®Google Scholar
• Madu IG, Roth SL, Belouzard S, Whittaker GR. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J Virol. 2009;83(15):7411–7421. doi:10.1128/JVI.00079-09
   PubMed Web of Science ®Google Scholar
• Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261. doi:10.1146/annurev-virology-110615-042301
   PubMed Web of Science ®Google Scholar
• Long QX, Liu B-Z, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–848.
   PubMed Web of Science ®Google Scholar
• Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30:3306–3309.
   PubMed Web of Science ®Google Scholar
• Renegar KB, Small PA, Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004;173(3):1978–1986. doi:10.4049/jimmunol.173.3.1978
   PubMed Web of Science ®Google Scholar
• Béné MC, de Carvalho Bittencourt M, Eveillard M, Le Bris Y. Good IgA bad IgG in SARS-CoV-2 infection? Clin Infect Dis. 2020;71(15):897–898. doi:10.1093/cid/ciaa426
   PubMed Web of Science ®Google Scholar
• Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol. 2000;37(18):1141–1149. doi:10.1016/S0161-5890(01)00025-6
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–1066. doi:10.1111/j.1469-0691.2004.01009.x
   PubMed Web of Science ®Google Scholar
• Mo H, Zeng G, Ren X, et al. CHAN‐YEUNG M: longitudinal profile of antibodies against SARS‐coronavirus in SARS patients and their clinical significance. Respirology. 2006;11(1):49–53. doi:10.1111/j.1440-1843.2006.00783.x
   PubMed Web of Science ®Google Scholar
• Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824. doi:10.3201/eid2210.160706
   PubMed Web of Science ®Google Scholar
• Roltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54):eabe0240. doi:10.1126/sciimmunol.abe0240
   PubMed Web of Science ®Google Scholar